Study wrapper · #1270
Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.
Editor's note
The reassuring finding — PCOS does not appear to blunt tirzepatide's weight response — is worth having, since PCOS is usually described as making weight loss harder. But the 10-month comparison rests on 40 women with PCOS and 397 without, out of a starting cohort of 54,114, so attrition and survivor bias dominate that timepoint and the confidence interval spans -22.4 to -16.4 percent. PCOS status was self-reported, not chart-confirmed, and the cohort comes from a commercial weight-management service. The digital-engagement finding is observational and cannot separate the tools from the kind of person who uses them.
Plain-language abstract
A UK digital weight-management service reviewed records for 54,114 women prescribed tirzepatide, 4,241 of whom reported having PCOS. Among those reaching the 10-month mark, women with PCOS lost about 19.4 percent of body weight versus 18.7 percent for women without it — no meaningful difference. Women with PCOS who engaged with the service's digital tools lost about 3.4 percentage points more.